OTCMKTS:RLMD - Relmada Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.90 0.00 (0.00 %) (As of 08/20/2018 01:46 AM ET)Previous Close$0.90Today's Range$0.90 - $0.9052-Week Range$0.61 - $1.94Volume3,400 shsAverage Volume15,193 shsMarket Capitalization$15.30 millionP/E RatioN/ADividend YieldN/ABeta0.12 Company ProfileAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Relmada Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is based in New York, New York. Receive RLMD News and Ratings via Email Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolOTCMKTS:RLMD CUSIPN/A Webwww.relmada.com Phone212-547-9591 Debt Debt-to-Equity Ratio-0.68 Current Ratio0.81 Quick Ratio0.81 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.12 per share Price / Book7.50 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-6,280,000.00 Net MarginsN/A Return on Equity-2,175.64% Return on Assets-146.14% Miscellaneous Employees3 Outstanding Shares12,240,000Market Cap$15.30 million Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions What is Relmada Therapeutics' stock symbol? Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD." When is Relmada Therapeutics' next earnings date? Relmada Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 20th 2018. View Earnings Estimates for Relmada Therapeutics. Who are some of Relmada Therapeutics' key competitors? Some companies that are related to Relmada Therapeutics include BELLUS Health (BLUSF), Helix Biopharma (HBPCF), Eyenovia (EYEN), Humanigen (HGEN), Evofem Biosciences (EVFM), Novus Therapeutics (NVUS), Vascular Biogenics (VBLT), IntelGenx Technologies (IGXT), Addex Pharmaceuticals (ADDXF), Zosano Pharma (ZSAN), Celsion (CLSN), Moleculin Biotech (MBRX), vTv Therapeutics (VTVT), Avenue Therapeutics (ATXI) and Heat Biologics (HTBX). Who are Relmada Therapeutics' key executives? Relmada Therapeutics' management team includes the folowing people: Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO, Interim CFO, Principal Accounting Officer & Director (Age 58)Mr. Michael D. Becker, Consultant (Age 49)Dr. Richard M. Mangano Ph.D., Consultant (Age 68)Dr. Ottavio V. Vitolo, Sr. VP, Head of R&D & Chief Medical Officer (Age 45)Dr. Fai Jim Ph.D., VP of Chemistry, Manufacturing and Controls Has Relmada Therapeutics been receiving favorable news coverage? Media headlines about RLMD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Relmada Therapeutics earned a daily sentiment score of 0.16 on Accern's scale. They also gave news headlines about the company an impact score of 46.69 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Relmada Therapeutics. How do I buy shares of Relmada Therapeutics? Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Relmada Therapeutics' stock price today? One share of RLMD stock can currently be purchased for approximately $0.90. How big of a company is Relmada Therapeutics? Relmada Therapeutics has a market capitalization of $15.30 million. Relmada Therapeutics employs 3 workers across the globe. How can I contact Relmada Therapeutics? Relmada Therapeutics' mailing address is 750 Third Avenue 9th Floor, NEW YORK NY, 10017. The company can be reached via phone at 212-547-9591 or via email at [email protected] MarketBeat Community Rating for Relmada Therapeutics (OTCMKTS RLMD)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 68 (Vote Outperform)Underperform Votes: 62 (Vote Underperform)Total Votes: 130MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe RLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?